2023 Annual Report on Form 20-F We are a focused biopharma company with strong momentum and big ambitions We prevent and treat disease with vaccines, specialty & general medicines We prevent and treat disease with vaccines, specialty & general medicines We focus on the science of the immune...
Annual Report 2020 (PDF - 4.8MB) ESG Performance Summary 2020 (PDF - 3.2MB) 20 F 2020 (PDF - 4.6MB) Xbrl Interactive Data File 2020 (ZIP - 813.1KB) Download all Corporate reporting 2020 04 March 2020 Corporate reporting 2019 Annual Report 2019 (PDF - 4.1MB) 20-F 2019 (PD...
are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK’s 2021 Q4 Results and any impacts of the...
GlaxoSmithKline. (2020). Annual Report 2020. Retrieved fromhttps://www.gsk.com/media/6662/annual-report-2020.pdf GlaxoSmithKline. (2020). Key Facts. Retrieved fromhttps://www.gsk.com/en-gb/about-us/key-facts/ GlaxoSmithKline. (2020). Our Products. Retrieved fromhttps://www.gsk.com/en-gb...
GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 GSK plc at a glance Our purpose We unite science, technology and talent to get ahead of disease together For health impact + shareholder returns + thriving people About our new logo The new logo reflects our new purpose and growth ...
are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK’s Q3 Results and any impacts of the COVID-19 pandemic....
GSK Annual Report 2023 Quarterly results You might also like Our products We research and develop a broad range of innovative products Pharmaceuticals and Vaccines Career opportunities at GSK Discover the work we do and the opportunities that exist, from research and development through to making our...
We remain firmly on track with all our strategic goals. We delivered strong performance in our growth drivers and disciplined cost control to offset the unexpected impact in vaccines and so delivered our guidance for the year, which was set before the pandemic with report of sales up 3% CER ...
, approved for the treatment of multiple myeloma patients who have received at least one prior line of therapy. The antibody drug is J&J’s second largest revenue generator overall and its top cancer product, accounting for $7.9 billion in 2022 sales, according to the company’s annual ...
are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include but are not limited to those described under Item 3.D 'Risk factors” in the company's Annual Report on For...